The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.b

Opportunistic pulmonary/systemic infections

Publications

Lussana F, Cattaneo M, Rambaldi A, Squizzato A

Ruxolitinib-associated infections: A systematic review and meta-analysis.

American journal of hematology 2018 03;93;339-347 — 2018 03 — 339-347

Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.

Case reports in hematology 2016;2016;2389038 — 2016 — 2389038

Wysham NG, Sullivan DR, Allada G

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Chest 2013 May;143;1478-1479 — 2013 May — 1478-1479